Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bispecific antibody targeting CD45RB and Tim1
- Development stage
- Preclinical
- Lead developer
- Sichuan Provincial People's Hospital
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous, Subcutaneous
01
Overview
The bispecific antibody targeting CD45RB and Tim1 is a preclinical-stage bispecific monoclonal antibody being developed by Sichuan Provincial People's Hospital and Massachusetts General Hospital (MGH). It simultaneously targets Receptor-type tyrosine-protein phosphatase C (PTPRC, specifically the CD45RB isoform) and Hepatitis A virus cellular receptor 1 (HAVCR1, also known as Tim1). This dual-targeting approach is designed to induce and maintain regulatory B cells (Bregs), promoting immune tolerance and prolonging allogeneic islet graft survival in transplantation models. Preclinical studies have demonstrated that treatment with this bispecific antibody upregulates the expression of activation-induced cytidine deaminase (AICDA/AID) in Tim1+ Bregs, which plays a key role in Breg-mediated immunoregulation and transplant tolerance.
- Other names
- anti-CD45RB x anti-Tim1 bispecific antibodyanti-CD-45RB x anti-Tim1 bispecific antibodyanti-CD 45RB x anti-Tim1 bispecific antibodyanti-CD45RB/Tim1 bispecific antibodybispecific antibody targeting CD45RB and Tim-1
02
Targets
IL10 (Interleukin-10)TIM-1 (T-cell immunoglobulin and mucin domain-containing protein 1)CD45RA (T-cell surface glycoprotein CD45 isoform RA)
Beyond the preview
Go deeper on bispecific antibody targeting CD45RB and Tim1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bispecific antibody targeting CD45RB and Tim1.